GEMODIVEQ
Live / Registered — Registered (as of 07 Nov 2023)
What this means for you
Registered since 07 Nov 2023. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 07 Nov 2029: the §8 declaration of use).
Record
- Serial number
- 88902185
- Registration number
- 7213583
- Mark type
- Word mark
- Filed
- 05 May 2020
- Published for opposition
- 04 Aug 2020
- Registered
- 07 Nov 2023
- Next maintenance filing
- §8 declaration of use, due by 07 Nov 2029 (grace period to 07 May 2030)
- Attorney of record
- Andrea Christensen
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of genetic diseases and disorders; pharmaceutical preparations for the treatment of muscular dystrophy
Owner
- Pfizer Inc., New York, NY, US
- Pfizer Inc., New York, NY, US
- Pfizer Inc., New York, NY, US
Prosecution history
- 07 Nov 2023 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 07 Nov 2023 — REGISTERED-PRINCIPAL REGISTER
- 05 Oct 2023 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 04 Oct 2023 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 03 Oct 2023 — STATEMENT OF USE PROCESSING COMPLETE
- 27 Sept 2023 — USE AMENDMENT FILED
- 27 Sept 2023 — TEAS STATEMENT OF USE RECEIVED
- 06 Apr 2023 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 06 Apr 2023 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 06 Apr 2023 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 06 Apr 2023 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 06 Apr 2023 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 01 Mar 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 28 Feb 2023 — SOU EXTENSION 5 GRANTED
- 10 Feb 2023 — SOU EXTENSION 5 FILED